The global Patient-Derived Xenograft/PDX models market size is projected to reach USD 299 million by 2026 from USD 140 million in 2021, at a CAGR of 16.4% during the forecast period. Market growth is driven mainly by factors such as growing demand for personalized medicine, continuous support for cancer research, and growth in pharma R&D. Rising demand for humanized PDX models is expected to provide growth opportunity for players in the PDX models market. However, the high cost of personalized PDX models, stringent guidelines regarding the ethical use of animals in cancer research, and limitations associated with PDX models are expected to restrain the growth of this market to a certain extent during the forecast period.
The global PDX models market is highly consolidated. Key players in the PDX models market include JSR Corporation (Japan), WuXi AppTec (China), Champions Oncology, Inc. (US), The Jackson Laboratory (US), Oncodesign (France), Charles River Laboratories (US), Hera Biolabs (US), EPO Berlin-Buch (Germany), Envigo (US), Xentech (France), Urosphere (France), and Explora BioLabs (US). Partnerships, agreements, and collaborations are the key growth strategies undertaken by these companies to maintain their positions in the market.
To know about the assumptions considered for the study download the pdf brochur
JSR Corporation (Japan): The company operates in the market through its subsidiary, Crown Bioscience Inc. The company’s leading position is attributed to its strong brand image, robust product portfolio, and product development focus. The company offers products through well-established brands such as HuPrime, HuKemia, HuBase, HuMark, HuTrials, and HuSignature. It has emphasized product launches, agreements, collaborations, and expansions in the last three years.
WuXi AppTec (China): WuXi AppTec adopted organic and inorganic strategies such as acquisitions, product launches, and expansions to strengthen its market position. In April 2018, the company announced a new R&D center to strengthen its development and manufacturing platform, enabling drug developers to accelerate their projects from the preclinical to the commercial stage. The company’s product portfolio includes over 1,000 PDX models. The group specifically invested in animal models to serve quality products and services to customers. Its R&D expenses of the company grew at a rate of 41.2% from 2018 to 2019. The company has over 350 scientists at its facilities in Shanghai, Suzhou, and Nantong (China).
The Jackson Laboratory (US): The company has a wide product portfolio of over 400 PDX models. In 2019, the company distributed 3 million JAX mice to approximately 1,400 organizations in 50 countries. The company has received many grants, which support the development of its PDX models business. Over the last few years, the company has received grants/funds from leading health organizations and academic institutes such as the National Cancer Institute (NCI), National Institutes of Health (NIH), The Mark Foundation for Cancer Research, National Institute on Deafness and Other Communication Disorders, National Institute of Neurological Disorders and Stroke, and Howard Hughes Medical Institute (US). These grants have helped the company to develop new models and conduct specific studies on the models.
Patient-Derived Xenograft/PDX Model Market by Type (Mouse, Rat), Tumor Type (Gastrointestinal, Gynecological, Hematological), Application (Preclinical Drug Development, Biomarker analysis), End User (Pharma, Biotech, CROs) - Global Forecast to 2026
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE